This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
Journal of Hematology & Oncology Open Access 05 April 2023
-
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Journal of Hematology & Oncology Open Access 08 February 2019
-
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
Journal of Hematology & Oncology Open Access 24 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136–5145.
Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104: 1624–1630.
Rodriguez CO Jr., Stellrecht CM, Gandhi V . Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003; 102: 1842–1848.
Roecker AM, Stockert A, Kisor DF . Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol 2010; 4: 133–141.
Gandhi V, Plunkett W, Rodriguez CO Jr., Nowak BJ, Du M, Ayres M et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 1998; 16: 3607–3615.
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000; 18: 995–1003.
Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23: 3376–3382.
DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007; 109: 5136–5142.
Gokbuget N, Basara N, Baurmann H, Beck J, Bruggemann M, Diedrich H et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011; 118: 3504–3511.
Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transpl 2013; 19: 1124–1126.
Cohen MH, Johnson JR, Massie T, Sridhara R, McGuinn WD Jr, Abraham S et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006; 12: 5329–5335.
Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 2753–2759.
Bene MC, Groupe d'Etude Immunologique des L, European Group for the Immunological Classification of L. Pro-T ALL: immunophenotypical analyses. J Biol Regul Homeost Agents 2004; 18: 327–330.
Meijerink JP . Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010; 23: 307–318.
Cancer Therapy Evaluation Program. CTCAE criteria, Version 3.0. (Internet). CTCAE 2012.
Acknowledgements
This study was supported partly by GlaxoSmithKline Pharmaceuticals (to SF).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Author Contributions
PJ, HK and SF designed the study. PJ, RG, MC-T, DT, SOB and SF analyzed the results. PJ, HK, RG, MC-T, DT, SOB and SF wrote the paper. HK, DT, ND, NP, FR, MK, JB, SOB, EJ, JC, GB, TK and SF contributed the patient samples. All authors reviewed and gave the final approval for the paper.
Rights and permissions
About this article
Cite this article
Jain, P., Kantarjian, H., Ravandi, F. et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28, 973–975 (2014). https://doi.org/10.1038/leu.2013.312
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.312
This article is cited by
-
Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
Journal of Hematology & Oncology (2023)
-
Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Annals of Hematology (2022)
-
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Journal of Hematology & Oncology (2019)
-
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant
Bone Marrow Transplantation (2019)
-
Relapsed T Cell ALL: Current Approaches and New Directions
Current Hematologic Malignancy Reports (2019)